08 - Heart Failure (Part 5): SGLT2 Inhibitors
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
08 - Heart Failure (Part 5): SGLT2 Inhibitors
-
ナレーター：
-
著者：
このコンテンツについて
In this episode of Key Perspectives, we continue our heart failure series with Part 6: a deep dive into SGLT2 inhibitors. Originally developed for diabetes, these medications have become essential tools in managing both HFrEF and HFpEF, regardless of whether a patient has diabetes.
We’ll explore how SGLT2 inhibitors work, their surprising benefits in heart failure and chronic kidney disease, and the mechanisms that make them effective beyond glycemic control. We also discuss key topics such as:
-
How SGLT2 inhibitors reduce preload and afterload
-
Their metabolic benefits in the failing heart
-
Contraindications and when to hold therapy
-
Dosing strategies and how they interact with diuretics
-
How to recognize and manage euglycemic DKA
-
Cautions related to renal function, infection risk, and more
Whether you're managing patients in a SNF, clinic, or home setting, this episode offers practical insights for safely incorporating SGLT2 inhibitors into your treatment approach.